Royal London Asset Management Ltd. Raises Stake in Pfizer Inc. (NYSE:PFE)

Royal London Asset Management Ltd. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,461,076 shares of the biopharmaceutical company's stock after purchasing an additional 67,788 shares during the period. Royal London Asset Management Ltd.'s holdings in Pfizer were worth $65,292,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its position in Pfizer by 11.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock worth $3,766,366,000 after acquiring an additional 12,864,343 shares during the last quarter. Nordea Investment Management AB boosted its stake in Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock valued at $108,002,000 after acquiring an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI lifted its position in shares of Pfizer by 118.7% in the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after buying an additional 159,984 shares during the last quarter. NFJ Investment Group LLC lifted its position in shares of Pfizer by 12.8% in the 3rd quarter. NFJ Investment Group LLC now owns 384,571 shares of the biopharmaceutical company's stock worth $11,129,000 after buying an additional 43,719 shares during the last quarter. Finally, Daiwa Securities Group Inc. increased its holdings in shares of Pfizer by 25.9% in the 3rd quarter. Daiwa Securities Group Inc. now owns 804,522 shares of the biopharmaceutical company's stock worth $23,283,000 after acquiring an additional 165,611 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Pfizer Trading Up 0.1 %

Shares of PFE traded up $0.01 during mid-day trading on Friday, reaching $26.20. 349,778,786 shares of the company were exchanged, compared to its average volume of 36,645,908. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a market capitalization of $148.61 billion, a PE ratio of 18.58, a PEG ratio of 0.64 and a beta of 0.61. The business has a 50 day simple moving average of $26.17 and a two-hundred day simple moving average of $27.04.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Bank of America reiterated a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Guggenheim restated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.